Tag: Saracatinib

As of 2025, saracatinib is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) for patient use. Therefore, the question of **how much does saracatinib cost?** for a patient is moot, as there is no official commercial price; any costs found are for research-grade chemicals sold to laboratories.

As of September 2025, the investigational drug saracatinib has not received marketing approval from the U.S. Food and Drug Administration (FDA) and is not commercially available in the USA. The drug, originally developed for cancer, is now primarily being studied for other conditions, with access limited to participants in clinical trials or expanded access programs.